Chemours stock gains 1.20 percent as UBS cuts target

Published on 10/05/2026 at 20:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chemours stock trades at USD 13.88 after UBS cut its target to USD 16 on October 5, 2026. Second-quarter revenue reached USD 1.591 billion, while GAAP losses persisted.

CC, US1638511089, Illustration mit AI erstellt.

The Chemours Company stock (ISIN US1638511089) was trading at USD 13.88 on the NYSE at 2:53 p.m. ET on October 5, 2026, up 1.20 percent from the prior close. The immediate catalyst was UBS cutting its price target to USD 16 from USD 18 while keeping a Neutral rating, as Markets Insider reported on October 5, 2026.

UBS trims its valuation view

UBS reduced the target by USD 2, or 11.1 percent, leaving the new target USD 2.12 above the intraday price. That gap matters because the target change points to a more cautious valuation view even as CC gained during the October 5 session.

The latest analyst picture is broader than the UBS note. MarketBeat reported a Hold consensus from 12 analysts, comprising five Buy, five Hold and two Sell ratings, with an average price target of USD 20.10. That average stood USD 6.22 above the October 5 intraday price, a 44.8 percent difference.

Q2 loss contrasts with cash flow

Chemours reported USD 1.591 billion in second-quarter 2026 revenue, down from USD 1.615 billion in the second quarter of 2025. The company also posted a GAAP net loss of USD 274 million, compared with a USD 380 million loss a year earlier, while adjusted EBITDA was USD 247 million, according to the company's September 9, 2026 investor presentation filed with the SEC.

Cash generation provided the constructive counterpoint: second-quarter free cash flow was USD 114 million, up 128 percent from USD 50 million in the prior-year quarter. The same presentation showed operating cash flow of USD 158 million and net leverage of 4.4 times as of June 30, 2026.

PFAS liability stays in the picture

The company also faces a long-dated environmental obligation. StockTitan reported on September 10, 2026, that Chemours, DuPont and Corteva agreed to a USD 455 million North Carolina PFAS settlement payable over 15 years.

Stock value and trading range

CC's October 5 intraday price of USD 13.88 was USD 3.23 above the 52-week low of USD 10.44 and USD 14.79 below the 52-week high of USD 28.67. The company had a market capitalization of USD 2.1 billion and volume of 1,107,955 shares at the quoted time.